ALX Oncology Holdings Inc. (ALXO)

15,36 -1,26 (-7,58 %) À la clôture : 04:00PM EDT

ALX Oncology Holdings Inc.

323 Allerton Avenue
South San Francisco, CA 94080
United States
650 466 7125
https://www.alxoncology.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 72

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Corey S. Goodman Ph.D.	Executive Chairman	84k	S.O.	1952
Mr. Jason W. Lettmann	CEO & Director	60,5k	S.O.	1977
Dr. Jaume Pons Ph.D.	Founder, President, Chief Scientific Officer & Director	856,29k	S.O.	1967
Mr. Peter S. Garcia M.B.A.	Chief Financial Officer	631,11k	S.O.	1962
Dr. Sophia Randolph M.D., Ph.D.	Chief Medical Officer & Director	637,24k	S.O.	1968
Dr. Michael Chang Ph.D.	Vice President of Operations	S.O.	S.O.	S.O.
Ms. Shelly Pinto	Senior VP of Finance & Chief Accounting Officer	508,26k	S.O.	1977
Caitlyn Doherty	Manager of Investor Relations & Corporate Communications	S.O.	S.O.	S.O.
Dr. Christopher Byrd J.D., Ph.D.	General Counsel	S.O.	S.O.	S.O.
Dr. Athanasios Tsiatis M.D.	Senior Vice President of Clinical Development	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de ALX Oncology Holdings Inc. en date du 1 mai 2024 est 7. Les scores principaux sont Audit : 7; Société : 6; Droits des actionnaires : 8; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.